Avodart · DIN 02247813 · 0.5 mg · capsule
Limited Use, Reason for Use code 384, 385 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 384, 385 required
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Avodart (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Avodart · DIN 02247813
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2005-09-27
Health Canada: Marketed since 2003-11-14 · brand AVODART · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Glaxosmithkline inc · schedule Prescription
Ministry pays: $0.2565 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247813)
Source record
DIN 02247813: Avodart
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000524; group id 911; item number 2185; lccId 00166; manufacturer id GSK
Source form: Cap; strength: 0.5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.2717; ministry $0.2565
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247813
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72107
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565
Auro-Dutasteride · DIN 02469308 · $0.2565
Dutasteride · DIN 02429012 · $0.2565
Dutasteride · DIN 02443058 · $0.2565
Jamp Dutasteride · DIN 02484870 · $0.2565
Jamp Dutasteride Capsules · DIN 02546167 · $0.2565
Med-Dutasteride · DIN 02416298 · $0.2565
Mint-Dutasteride · DIN 02428873 · $0.2565
Priva-Dutasteride · DIN 02490587 · $0.2565
Sandoz Dutasteride · DIN 02424444 · $0.2565
Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247813
Shortage record checked October 6, 2026